Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:SLN
Previous Symbol
CUSIPN/A
Phone+44-20-34576900
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees50
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable
Silence Therapeutics (LON:SLN) Frequently Asked Questions
What is Silence Therapeutics' stock symbol?
Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."
How were Silence Therapeutics' earnings last quarter?
What price target have analysts set for SLN?
1 brokerages have issued twelve-month price objectives for Silence Therapeutics' stock. Their forecasts range from GBX 277 to GBX 277. On average, they expect Silence Therapeutics' stock price to reach GBX 277 in the next year. This suggests a possible upside of 386.0% from the stock's current price. View Analyst Price Targets for Silence Therapeutics.
What is the consensus analysts' recommendation for Silence Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silence Therapeutics.
Has Silence Therapeutics been receiving favorable news coverage?
News headlines about SLN stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Silence Therapeutics earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.
Who are some of Silence Therapeutics' key competitors?
Some companies that are related to Silence Therapeutics include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Silence Therapeutics' key executives?
Silence Therapeutics' management team includes the folowing people:
- Mr. David J. Ellam, CFO, Sec. & Director (Age 54)
- Dr. David Horn Solomon, CEO & Director (Age 58)
- Dr. Mark Cameron, Head of Chemistry
- Mr. Richard Jenkins, Head of Clinical Devel.
How do I buy shares of Silence Therapeutics?
Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Silence Therapeutics' stock price today?
One share of SLN stock can currently be purchased for approximately GBX 57.
What is Silence Therapeutics' official website?
How can I contact Silence Therapeutics?
Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.
MarketBeat Community Rating for Silence Therapeutics (LON SLN)
MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
